Driehaus Capital Management LLC Sells 5,821 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Driehaus Capital Management LLC lowered its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 1.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 535,717 shares of the specialty pharmaceutical company’s stock after selling 5,821 shares during the period. Driehaus Capital Management LLC’s holdings in KalVista Pharmaceuticals were worth $6,311,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of KALV. Campbell & CO Investment Adviser LLC bought a new position in shares of KalVista Pharmaceuticals in the 4th quarter valued at about $507,000. Frazier Life Sciences Management L.P. grew its position in shares of KalVista Pharmaceuticals by 11.8% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,622,294 shares of the specialty pharmaceutical company’s stock valued at $44,373,000 after acquiring an additional 383,435 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of KalVista Pharmaceuticals by 101.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 8,024 shares of the specialty pharmaceutical company’s stock valued at $95,000 after acquiring an additional 4,043 shares during the period. BNP Paribas Financial Markets grew its position in shares of KalVista Pharmaceuticals by 94.5% in the 1st quarter. BNP Paribas Financial Markets now owns 18,013 shares of the specialty pharmaceutical company’s stock valued at $214,000 after acquiring an additional 8,750 shares during the period. Finally, ClariVest Asset Management LLC bought a new position in shares of KalVista Pharmaceuticals in the 1st quarter valued at about $659,000.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on KALV shares. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, September 6th. Needham & Company LLC reiterated a “buy” rating and issued a $32.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, September 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, September 9th.

KalVista Pharmaceuticals Stock Up 23.4 %

KALV stock opened at $12.34 on Monday. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.21 and a 12 month high of $16.88. The firm has a market cap of $520.60 million, a P/E ratio of -3.63 and a beta of 0.89. The company’s 50-day moving average price is $12.47 and its two-hundred day moving average price is $12.10.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.04. Equities analysts predict that KalVista Pharmaceuticals, Inc. will post -3.35 EPS for the current year.

Insider Buying and Selling at KalVista Pharmaceuticals

In related news, insider Paul K. Audhya sold 2,135 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $12.40, for a total transaction of $26,474.00. Following the sale, the insider now directly owns 83,745 shares of the company’s stock, valued at approximately $1,038,438. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Paul K. Audhya sold 2,135 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $12.40, for a total transaction of $26,474.00. Following the sale, the insider now directly owns 83,745 shares of the company’s stock, valued at approximately $1,038,438. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Christopher Yea sold 7,102 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $12.01, for a total transaction of $85,295.02. Following the sale, the insider now directly owns 84,467 shares in the company, valued at $1,014,448.67. The disclosure for this sale can be found here. Insiders have sold a total of 30,804 shares of company stock valued at $372,112 in the last ninety days. 12.30% of the stock is currently owned by company insiders.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.